[
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT): A Healthcare Leader Offering Dividend Value and Growth",
    "summary": "Abbott Laboratories (NYSE:ABT) is included among the 11 Best Value Dividend Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) produces a wide range of healthcare products and medical devices, with its business divided into four main areas: established pharmaceuticals, diagnostics, nutrition, and medical devices. On September 19, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 […]",
    "url": "https://finnhub.io/api/news?id=1712d0f5291ccbc7be504d4bc271a457f25f51ec99654913c03cb00ca8703410",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759164082,
      "headline": "Abbott Laboratories (ABT): A Healthcare Leader Offering Dividend Value and Growth",
      "id": 136934111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories (NYSE:ABT) is included among the 11 Best Value Dividend Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) produces a wide range of healthcare products and medical devices, with its business divided into four main areas: established pharmaceuticals, diagnostics, nutrition, and medical devices. On September 19, Abbott Laboratories (NYSE:ABT) declared a quarterly dividend of $0.59 […]",
      "url": "https://finnhub.io/api/news?id=1712d0f5291ccbc7be504d4bc271a457f25f51ec99654913c03cb00ca8703410"
    }
  },
  {
    "ts": null,
    "headline": "Synlait Milk agrees North Island asset sale to Abbott Laboratories",
    "summary": "The assets, including the Pokeno factory, amount to around half of Synlait’s average market capitalisation.",
    "url": "https://finnhub.io/api/news?id=2143b7de5ec3242ba504975b29ed42995884d196b5359eeccaf68bd2918b8c94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759152755,
      "headline": "Synlait Milk agrees North Island asset sale to Abbott Laboratories",
      "id": 136915754,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The assets, including the Pokeno factory, amount to around half of Synlait’s average market capitalisation.",
      "url": "https://finnhub.io/api/news?id=2143b7de5ec3242ba504975b29ed42995884d196b5359eeccaf68bd2918b8c94"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=14f295da455af19f5d7ce1db9ed3794adad75c9cb235254185c4cfb2a76bf569",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759150803,
      "headline": "Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 136915755,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=14f295da455af19f5d7ce1db9ed3794adad75c9cb235254185c4cfb2a76bf569"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's Dissolving Stent Receives Health Canada Approval for Treating Blocked Arteries Below-the-Knee",
    "summary": "Abbott (NYSE: ABT) today announced that Health Canada has authorized the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a first-of-its kind treatment innovation for people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug, everolimus, to support vessel healing prior to completely dissolving.",
    "url": "https://finnhub.io/api/news?id=b0c3b249124ddd63934406678cdae7311668e483ca93aa1b80a7856319e95ccb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759147200,
      "headline": "Abbott's Dissolving Stent Receives Health Canada Approval for Treating Blocked Arteries Below-the-Knee",
      "id": 136915756,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced that Health Canada has authorized the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a first-of-its kind treatment innovation for people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). The Esprit BTK System is designed to keep arteries open and deliver a drug, everolimus, to support vessel healing prior to completely dissolving.",
      "url": "https://finnhub.io/api/news?id=b0c3b249124ddd63934406678cdae7311668e483ca93aa1b80a7856319e95ccb"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Abbott Laboratories' Next Quarterly Earnings Report",
    "summary": "Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
    "url": "https://finnhub.io/api/news?id=66d312a77ee4dae91e0a09e61711db81e173c0b4383bf684f1d06963ff310c53",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759139218,
      "headline": "What to Expect From Abbott Laboratories' Next Quarterly Earnings Report",
      "id": 136915757,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories will release its third-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
      "url": "https://finnhub.io/api/news?id=66d312a77ee4dae91e0a09e61711db81e173c0b4383bf684f1d06963ff310c53"
    }
  }
]